235 523

Cited 4 times in

Clinical follow-up of conjunctival malignant melanoma

DC Field Value Language
dc.contributor.author김민-
dc.contributor.author박혜성-
dc.contributor.author이상열-
dc.contributor.author최정범-
dc.date.accessioned2017-05-04T07:34:10Z-
dc.date.available2017-05-04T07:34:10Z-
dc.date.issued2005-
dc.identifier.issn1011-8942-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/147475-
dc.description.abstractPURPOSE: To investigate the clinical features and course of conjunctival malignant melanoma in Korea. METHODS: The medical records of 15 patients, 5 males and 10 females, diagnosed with conjunctival malignant melanoma who had been treated at Severance Hospital from May 1991 to March 2004 were reviewed retrospectively. The clinical parameters of the patients, tumors, and treatment were analyzed for their relation to outcome measures. RESULTS: The mean age at the time of diagnosis was 53.4 years (s). In all cases, the disease was unilateral and all patients had experienced at least one recurrence. Local lymph node metastasis was found in 3 patients (20%) and the mean time to metastasis was 3.5 years. Systemic metastasis was found in 6 patients (40%) and the mean time to metastasis was 9.3 years. There were 5 cases of tumor-related death (33.3%), 4 of which were attributed to systemic metastasis. The Kaplan-Meier estimates of cumulative survival rate were 90% at 30 months and 56.6% at 70 months. CONCLUSIONS: Although conjunctival malignant melanoma is a rare disease, it is life-threatening and complete tumor excision at an early stage is mandatory, as is additional therapy to prevent local recurrence and systemic metastasis.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherKJO-
dc.relation.isPartOfKorean Journal of Ophthalmology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHConjunctival Neoplasms/mortality-
dc.subject.MESHConjunctival Neoplasms/pathology*-
dc.subject.MESHConjunctival Neoplasms/physiopathology*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLymphatic Metastasis*-
dc.subject.MESHMale-
dc.subject.MESHMelanoma/mortality-
dc.subject.MESHMelanoma/physiopathology*-
dc.subject.MESHMelanoma/secondary*-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTime Factors-
dc.titleClinical follow-up of conjunctival malignant melanoma-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Ophthalmology (안과학교실)-
dc.contributor.departmentDept. of Ophthalmology (안과학교실)-
dc.contributor.departmentDept. of Ophthalmology (안과학교실)-
dc.contributor.departmentDept. of Ophthalmology (안과학교실)-
dc.contributor.googleauthorJungbum Choi-
dc.contributor.googleauthorMin Kim-
dc.contributor.googleauthorHae Song Park-
dc.contributor.googleauthorSang Yeul Lee-
dc.identifier.doi10.3341/kjo.2005.19.2.91-
dc.contributor.localIdA00455-
dc.contributor.localIdA01762-
dc.contributor.localIdA02819-
dc.contributor.localIdA04178-
dc.relation.journalcodeJ02931-
dc.identifier.eissn2092-9382-
dc.identifier.pmid15988922-
dc.contributor.alternativeNameKim, Min-
dc.contributor.alternativeNamePark, Hae Song-
dc.contributor.alternativeNameLee, Sang Yeul-
dc.contributor.alternativeNameChoi, Jung Bum-
dc.citation.volume19-
dc.citation.number2-
dc.citation.startPage91-
dc.citation.endPage95-
dc.identifier.bibliographicCitationKorean Journal of Ophthalmology, Vol.19(2) : 91-95, 2005-
dc.date.modified2017-05-04-
dc.identifier.rimsid40255-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.